Episodes

From Patient Involvement to Patient Leadership: A Conversation with Donna Cryer, JD Real Pharma, hosted by Na-Ri Oh and Ian Wendt Episode Summary As AI moves deeper into drug development, from trial design to evidence generation, the more pressing question isn't what the technology can do. It's who has the authority to decide how it's used. In this episode, Na-Ri and Ian sit down with Donna Cryer, JD, founder of the Global Liver Institute, longtime FDA patient representative, and the person cr...

Episode Summary In this episode of Real Pharma, hosts Na-Ri Oh and Ian Wendt sit down with Kristiaan Rawlings, Executive Director at EPM Scientific, to unpack what is really happening in the biopharma talent market right now. From the surprising resurgence of market access hiring to the growing influence of AI in recruiting and candidate preparation, this conversation explores the forces reshaping commercial talent strategy in 2026. The group also digs into salary inflation, title compression, ...

🧠 Episode Summary What if we’ve been thinking about cancer all wrong? In this deeply personal and paradigm-shifting episode of RealPharma, hosts Dr. Na-Ri Oh and Ian Wendt sit down with Dr. Christopher Gregg—neuroscientist, entrepreneur, and stage 4 cancer patient—to explore a bold new vision for cancer care. Dr. Gregg shares how his own diagnosis sparked a radical rethink of oncology: moving away from the “war on cancer” mindset toward managing it as a chronic, controllable condition. Drawin...

The Opioid Reckoning (Part 2): Litigation, Accountability, and the Fight for Justice with Paul T. Farrell Jr. In Part 2 of our deep dive into the opioid crisis, hosts Dr. Na-Ri Oh and Ian Wendt continue their conversation with Paul T. Farrell Jr., the West Virginia attorney who helped lead the historic national opioid litigation. This episode moves beyond the legal strategy discussed in Part 1 and explores the human toll, the documentary that captured the battle, the controversial trial outcom...

The Opioid Reckoning (Part 1): Paul Farrell Jr. on Litigation, Accountability, and the System That Failed West Virginia has had the highest drug overdose death rate in the United States for over a decade. In a state with fewer than 2 million people, 780 million prescription opioids were distributed in just six years. For Paul Farrell Jr., a Huntington, West Virginia native and mass tort attorney, those numbers weren’t abstract statistics. They were neighbors. Friends. Family members. In Part ...

Ending the Diagnostic Odyssey: Rare Disease, Employers & Reimagining Health Plans Hosts: Na-Ri Oh & Ian Wendt Guest: Joshua Resnikoff, Founder & CEO, Sunstone Health Episode Overview What if the biggest innovation in rare disease wasn’t a new drug—but a new way to navigate the system? In this episode, Na-Ri and Ian sit down with Joshua Resnikoff, biomedical engineer turned founder of Sunstone Health, to explore how employers can fundamentally rethink healthcare spending—while dramatically im...

🎙️ Beyond Survival: Why Empathy Is the Missing Prescription in Pharma Episode Summary: In this no-holds-barred conversation, Na-Ri Oh and Ian Wendt sit down with Matthew Zachary—brain cancer survivor, founder of Stupid Cancer, host of Out of Patients, and a relentless disruptor in patient advocacy. At 21, Matthew was diagnosed with brain cancer and faced a life-altering decision: take chemotherapy and lose his identity as a musician, or reject treatment and risk everything. That decision becam...

🎙️ Real Pharma – Episode Title: Breaking the Silence: Why Pharma Needs to Speak Up Hosts: Na-Ri Oh & Ian Wendt Guest: Brian Reid, Founder & Principal at Reid Strategic 🔍 Episode Summary: In this episode of Real Pharma, Na-Ri and Ian sit down with Brian Reid—a healthcare communicator, strategist, and former journalist who's worked across government, pharma, and media—to explore a provocative question: Why is the pharmaceutical industry so quiet when it comes to telling its own story? Together...

🎧 Hosts: Na-Ri Oh & Ian Wendt 🎓 Special Guests: Emma Cousin (PhD Candidate, Choice Institute – UW), Amos Fung (RealPharma Intern & Student Pharmacist) 🔍 Episode Summary: In this thought-provoking episode, hosts Na-Ri Oh and Ian Wendt sit down with Emma Cousin, a PhD candidate at the Choice Institute, University of Washington, to unpack the real-world implications of the Inflation Reduction Act (IRA)—particularly the Medicare Drug Price Negotiation Program. Joining them is Amos Fung, a RealPha...

Reinventing Cell Therapy with Acoustics, Microfluidics & High-Throughput Engineering In this episode, hosts Na-Ri Oh and Ian Wendt sit down with Dr. Andrew Gray — immune cell engineer, biotech founder, venture capitalist, and CEO of CellEcho — to explore how a new acoustic-powered gene-delivery platform may redefine the boundaries of cell therapy. The conversation spans the current state of the cell therapy landscape, the persistent barriers to scalability, and why CellEcho’s ASOP platform (Aco...

👩‍🔬👨‍⚕️ Hosts: Na-Ri Oh & Ian Wendt 🎧 Guest: Dr. Ron Shigeta – Biotech visionary, co-founder of IndieBio, and food innovation expert. 🧬 Episode Summary: In this deeply insightful and refreshingly candid episode, Ian and Nari welcome back biotech veteran Dr. Ron Shigeta to explore the evolving landscape where food, health, and biotech collide. From the collapse of the lab-grown meat hype cycle to the challenges of democratizing access to functional food, Ron brings hard truths, historical cont...

🎙 Episode Title: From Job Search to Power Move: How Top Talent’s Playing 2025 🧠 Guests: Kristiaan Rawlings, Executive Director at EPM Scientific 🎧 Hosts: Na-Ri Oh & Ian Wendt Episode Summary Layoffs. AI. Resume black holes. The biopharma hiring market feels noisy—and not in a good way. But beneath the doomscrolling, there’s a more nuanced story unfolding. In this episode, Kristiaan Rawlings returns to RealPharma to deliver a data-backed pulse check on the state of hiring across the industry...

Where Policy Meets the Pharmacy Counter Featuring Congressman Jake Auchincloss Episode Summary In this episode of RealPharma, hosts Na-Ri Oh and Ian Wendt sit down with Congressman Jake Auchincloss (MA-04) to dissect the tangled web of policy, profit, and politics driving America’s drug pricing system. From pharmacy benefit managers (PBMs) to the politics of tariffs, this discussion explores the push for transparency, fair competition, and sustainable reform in healthcare. Auchincloss, a Mari...

Episode Title: “Conversations, Not Campaigns: The Art of Authentic Engagement in Healthcare” 🗣️ Episode Summary In this episode, hosts Dr. Na-Ri Oh and Ian Wendt sit down with Colin Hung — healthcare technologist, marketing strategist, and co-founder of the long-running #HCLDR (Healthcare Leadership) Twitter community. Colin shares his journey from biomedical engineering to becoming one of the most respected community builders in digital health. Together, they explore what authentic engagement...

🎙️ Episode Title: Building the Highway for AI in Pharma: A Conversation with Ilya Burkov 📍 Episode Summary In this episode of RealPharma, hosts Na-Ri Oh and Ian Wendt sit down with Dr. Ilya Burkov, Head of AI Cloud at Nebius, to explore the critical infrastructure enabling the AI revolution in drug development. While the headlines often focus on the promise of AI, Ilya brings us backstage—where the real acceleration happens. From GPU scalability and regulatory compliance to synthetic data and ...

🎙️ Episode Title: Inside the CMC Black Box: A Deep Dive with Reza Oliyai 🧾 Show Notes: What exactly is CMC — and why is it behind more FDA rejections than any other category? In this episode of RealPharma, hosts Na-Ri Oh and Ian Wendt sit down with Dr. Reza Oliyai, former SVP of Pharmaceutical & Biologics Operations at Gilead Sciences, and now Founder & CEO of Oliyai Consulting, to demystify the world of Chemistry, Manufacturing, and Controls (CMC). With over three decades of experience and a...

In this episode of RealPharma, Ian Wendt and Na-Ri Oh sit down with Dara Katcher Levy, a regulatory attorney at Hyman, Phelps & McNamara, P.C.—widely regarded as one of the nation’s top firms in food and drug law. Dara brings decades of expertise in promotional review, labeling negotiations, and post-market compliance, helping life sciences companies navigate the complex world of FDA regulations. Together, they unpack the most pressing regulatory questions facing biopharma in 2025: DTC Adverti...

Episode Title: From Rock Star to Rare Disease Revolutionary: Casey McPherson’s Fight for His Daughter’s Life In this deeply personal and inspiring conversation, hosts Na-Ri Oh and Ian Wendt sit down with Casey McPherson, founder and CEO of AlphaRose Therapeutics—and acclaimed recording artist—to explore how one father’s determination to save his daughter’s life is shaking up the rare disease drug development model. Casey shares his journey from fronting rock bands to founding a biotech company...

Episode Title: Behind the PBM Curtain: Antonio Ciaccia Exposes the Game Show Notes: In this compelling episode of Real Pharma, hosts Na-Ri Oh and Ian Wendt welcome back Antonio Ciaccia, CEO of 46brooklyn Research and President of 3 Axis Advisors, for a hard-hitting discussion on the power and pitfalls of pharmacy benefit managers (PBMs). PBMs remain one of the most opaque and influential forces in healthcare—shaping drug prices, patient access, and payer negotiations—often under the guise of ...

🎙️ 340B or Bust: Is This Program Failing the Sick? This week on Real Pharma, hosts Dr. Na-Ri Oh and Ian Wendt dive into the tangled world of 340B with returning guest William “Bill” Sarraille—one of the most respected voices in healthcare law, an active patient advocate, and a rare disease patient himself. The 340B Drug Pricing Program was intended to help vulnerable patients by requiring drug manufacturers to provide discounted medications to covered entities. But as Bill puts it, has the prog...

Episode Title: “Hiring Heat Check: What’s Hot in Biotech + Pharma Talent in Mid-2025” 🎙️ Hosts: Ian Wendt & Na-Ri Oh 🎧 Guest: Kristiaan Rawlings, Executive Recruiter at EPM Scientific Episode Overview: This week, fan favorite Kristiaan Rawlings returns to RealPharma to give us the raw and real insights on pharma and biotech hiring trends as we hit the midpoint of 2025. From compensation curves and BD boom times to the rise of GLP-1s and the return of oncology, this episode is your ultimate p...

🎙 Episode Title: The Future of Biotech Guest: Andrew Craig, Founder of Plain English Finance | Author of Our Future is Biotech 📌 Episode Summary In this bold and wide-ranging conversation, Ian Wendt and Na-Ri Oh sit down with Andrew Craig—British investor, entrepreneur, and author—to explore how biotechnology is poised to shape the next century in the same way physics and computing shaped the last. Craig draws on his decades of experience as a London and New York investment banker an...

🎙 Episode Title: Rooted in Results: The Future of Functional Medicine with Dr. Erica Armstrong 🧬 Episode Summary In this episode, Dr. Na-Ri Oh and Ian Wendt sit down with Dr. Erica Armstrong, board-certified family medicine physician and founder of Root Functional Medicine, to explore the promise, challenges, and evolution of functional medicine. Dr. Armstrong discusses how Root’s systems-based, data-driven approach is helping patients uncover the root causes of chronic disease, improve outco...

🎙️ RealPharma Podcast Episode Title: Cracking the Code on Patient Engagement: Conversational AI with Dan Fox 🗓️ Release Date: May 5, 2025 🎧 Hosts: Dr. Na-Ri Oh & Ian Wendt 🎤 Guest: Dan Fox, Managing Director of Healthcare at Drips Episode Summary: In this eye-opening episode, we welcome Dan Fox, a trailblazer in AI-powered patient communication, to explore how proactive outreach and conversational AI are reshaping healthcare engagement. As the Managing Director of Healthcare at Drips...